Neuroleptic Malignant Syndrome and Catatonia. A Report of Three Cases

Overview

Journal Eur Arch Psychiatry Clin Neurosci

Specialties Neurology
Psychiatry

Date 1994 Jan 1

PMID 7913834

Citations 6

Authors

M Raja

M C Altavista

S Cavallari

L Lubich

Affiliations

Soon will be listed here.

Abstract

In a series of 1007 consecutively admitted patients, 3 cases of neuroleptic malignant syndrome (NMS) were identified (0.3%). All three patients were affected by mood disorders with congruent psychotic features, had shown catatonia just before the onset of NMS, and had been treated with low neuroleptic doses. All of them presented low serum iron levels. The relationship between NMS and catatonia and possible therapeutic decisions are discussed.

Citing Articles

An Abnormal Case of Malignant Catatonia in a Previously Healthy Young Female With Unexplained Neurological Symptoms.

Kothari S, Khan B, Nguyen M, Gleason S J Med Cases. 2024; 15(12):382-386.

PMID: 39610913 PMC: 11602172. DOI: 10.14740/jmc4327.

Catatonia and the immune system: a review.

Rogers J, Pollak T, Blackman G, David A Lancet Psychiatry. 2019; 6(7):620-630.

PMID: 31196793 PMC: 7185541. DOI: 10.1016/S2215-0366(19)30190-7.

Catatonia: Our current understanding of its diagnosis, treatment and pathophysiology.

Rasmussen S, Mazurek M, Rosebush P World J Psychiatry. 2017; 6(4):391-398.

PMID: 28078203 PMC: 5183991. DOI: 10.5498/wjp.v6.i4.391.

A case of catatonia and neuroleptic malignant syndrome probably associated with antipsychotic in Korea.

Choi H, Kim K, Koo B Psychiatry Investig. 2011; 8(2):174-7.

PMID: 21852996 PMC: 3149114. DOI: 10.4306/pi.2011.8.2.174.

Neuroleptic malignant syndrome. Recognition, prevention and management.

Velamoor V Drug Saf. 1998; 19(1):73-82.

PMID: 9673859 DOI: 10.2165/00002018-199819010-00006.

References

Davis J, Janicak P, Sakkas P, Gilmore C, Wang Z . Electroconvulsive Therapy in the Treatment of the Neuroleptic Malignant Syndrome. Convuls Ther. 1991; 7(2):111-120. View

Levenson J . Neuroleptic malignant syndrome. Am J Psychiatry. 1985; 142(10):1137-45. DOI: 10.1176/ajp.142.10.1137. View

Adityanjee , Singh S, Singh G, Ong S . Spectrum concept of neuroleptic malignant syndrome. Br J Psychiatry. 1988; 153:107-11. DOI: 10.1192/bjp.153.1.107. View

Rosebush P, Stewart T . A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry. 1989; 146(6):717-25. DOI: 10.1176/ajp.146.6.717. View

Barnes T, Halstead S, Little P . Relationship between iron status and chronic akathisia in an in-patient population with chronic schizophrenia. Br J Psychiatry. 1992; 161:791-6. DOI: 10.1192/bjp.161.6.791. View

Keck Jr P, Pope Jr H, Cohen B, McElroy S, Nierenberg A . Risk factors for neuroleptic malignant syndrome. A case-control study. Arch Gen Psychiatry. 1989; 46(10):914-8. DOI: 10.1001/archpsyc.1989.01810100056011. View

White D, Robins A . Catatonia: harbinger of the neuroleptic malignant syndrome. Br J Psychiatry. 1991; 158:419-21. DOI: 10.1192/bjp.158.3.419. View

Keck Jr P, Pope Jr H, McElroy S . Frequency and presentation of neuroleptic malignant syndrome: a prospective study. Am J Psychiatry. 1987; 144(10):1344-6. DOI: 10.1176/ajp.144.10.1344. View

Shalev A, Munitz H . The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatr Scand. 1986; 73(4):337-47. DOI: 10.1111/j.1600-0447.1986.tb02694.x. View

10.

Gelenberg A, Bellinghausen B, Wojcik J, Falk W, Sachs G . A prospective survey of neuroleptic malignant syndrome in a short-term psychiatric hospital. Am J Psychiatry. 1988; 145(4):517-8. DOI: 10.1176/ajp.145.4.517. View

11.

Castillo E, Rubin R, Holsboer-Trachsler E . Clinical differentiation between lethal catatonia and neuroleptic malignant syndrome. Am J Psychiatry. 1989; 146(3):324-8. DOI: 10.1176/ajp.146.3.324. View

12.

Sachdev P, Loneragan C . Acute drug-induced akathisia is not associated with low serum iron status. Psychopharmacology (Berl). 1991; 103(1):138-9. DOI: 10.1007/BF02244089. View

13.

Nemes Z, Rotrosen J, Angrist B, Peselow E, Schoentag R . Serum iron levels and akathisia. Biol Psychiatry. 1991; 29(4):411-3. DOI: 10.1016/0006-3223(91)90229-f. View

14.

KELLAM A . The neuroleptic malignant syndrome, so-called. A survey of the world literature. Br J Psychiatry. 1987; 150:752-9. DOI: 10.1192/bjp.150.6.752. View

15.

Scheftner W, Shulman R . Treatment Choice in Neuroleptic Malignant Syndrome. Convuls Ther. 1992; 8(4):267-279. View

16.

Addonizio G, Susman V, Roth S . Symptoms of neuroleptic malignant syndrome in 82 consecutive inpatients. Am J Psychiatry. 1986; 143(12):1587-90. DOI: 10.1176/ajp.143.12.1587. View

17.

Neppe V . The neuroleptic malignant syndrome. A priority system. S Afr Med J. 1984; 65(13):523-5. View

18.

Pearlman C . Neuroleptic malignant syndrome: a review of the literature. J Clin Psychopharmacol. 1986; 6(5):257-73. View

19.

Pope Jr H, Keck Jr P, McElroy S . Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry. 1986; 143(10):1227-33. DOI: 10.1176/ajp.143.10.1227. View

20.

Rutledge J, Hilal S, Silver A, Defendini R, Fahn S . Study of movement disorders and brain iron by MR. AJR Am J Roentgenol. 1987; 149(2):365-79. DOI: 10.2214/ajr.149.2.365. View